SPONSORS & EXHIBITORS
On behalf of the Organising Committee, thank you to those businesses who have committed to supporting ANZSNM ASM 2022.
Platinum Sponsors
Telix is a commercial stage radiopharmaceutical company focused on the development of diagnostic and therapeutic “theranostic” products using Molecularly Targeted Radiation (MTR). Telix’s investigational products address significant unmet medical need in oncology, immunology, and rare diseases. Telix is headquartered in Melbourne with international operations in Belgium, Switzerland, Japan, and the United States. Telix was established in 2015 and is listed on the Australian Securities Exchange (ASX: TLX).
Most cancer drugs, including modern targeted therapies, are only able to kill a subset of cancer cells that exist within a tumour, enabling some to survive and continue to grow. MTR delivers highly targeted radiation selectively to the cancer cells regardless of their location within the body, destroying both the cancer cells themselves as well as the supporting cells and blood vessels within the tumour, while sparing adjacent healthy tissues.
Telix’s core development pipeline is focused on prostate, kidney, glioblastoma (brain) and hematologic (blood) cancers.
In November 2021, Telix received its first marketing authorisation approval for Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga PSMA-11 injection) for prostate cancer imaging, from the Australian TGA. TLX591-CDx has also been accepted for filing by the U.S. FDA, and marketing authorisation applications are being progressed in Europe and Canada.
TLX591-CDx combines gallium-68 (68Ga) with a marker known as prostate specific membrane antigen 11 (PSMA-11) to detect prostate cancer throughout the body, using positron emission tomography (PET). PSMA-PET is emerging as a new standard of care for prostate cancer imaging, having recently been included in the updated National Comprehensive Cancer Network® (NCCN) Guidelines®.
On the therapy side, Telix recently initiated its ProstACT program of trials investigating TLX591 in prostate cancer, which includes a global Phase III study.
Telix’s second investigational imaging product for kidney cancer, specifically, clear cell renal cell carcinoma cancer (ccRCC), TLX250-CDx (89Zr-DFO-girentuximab) is in the final stages of patient enrolment in a pivotal Phase III ‘ZIRCON’ study, conducted over 34 sites across Australia, Europe, and the United States.
During 2021, Telix commenced a Phase II study of investigational kidney cancer therapy TLX250 in combination with immunotherapy, and reported encouraging topline results in the IPAX-1 Ph I/II study of TLX101 in combination with external beam radiation therapy in recurrent glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer.
With the exception of Illuccix in Australia, none of Telix’s products have received a marketing authorisation in any jurisdiction.
Gold & Dinner Sponsor
ANSTO leverages great science to deliver big outcomes.
We partner with scientists and engineers and apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment.
ANSTO has been supporting the delivery of nuclear medicine for Australian patients for more than 60 years.
Gold & Barista Sponsor
Gold & WIFI Sponsor
Gold Sponsors
The Australian Radioactive Waste Agency (ARWA) is leading the process to responsibly manage our nation’s radioactive waste now and into the future.
We’re establishing a single, safe and purpose-built facility that will permanently dispose of Australia’s low-level radioactive waste and temporarily store its intermediate-level waste.
Radioactive materials have a range of uses. They’re used to diagnose and treat heart, lung and musculoskeletal conditions, and certain cancers. It’s likely that all Australians will benefit from nuclear medicine in their lifetime.
With these benefits comes a responsibility to safely manage radioactive waste.
Bayer Radiology ANZ supplies a niche range of high-quality equipment and services to the ANZ Molecular Imaging market.
We have extensive experience department design, equipment selection and planning for Nuclear Medicine, PET and Cyclotron facilities. Our product portfolio focuses on these specific areas, strongly aligning with our key experience as the first choice in industry.
We offer world leading product lines from Medrad, Mirion and Eckert and Ziegler to name a few. We specialise in injector and synthesis platforms for current and future theranostic demands supported by highly skilled sales and service personnel.
Canon Medical offers a full range of diagnostic medical imaging solutions including PET-CT, CT, Angiography and X-Ray, Ultrasound, MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.
Our PET-CT solution, Cartesion Prime, is a 100% air-cooled digital PET-CT with Advanced intelligent Clear-IQ Engine (AiCE) deep learning reconstruction for exceptional diagnostic detail and confidence. The Cartesion Prime is the bridge to the new horizon of molecular imaging: an AI-enabled future that sees improved image quality, faster scan time per bed, and superior performance. Visit Canon Medical at the booth during ANZSNM:
At United Imaging, we develop and produce advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011 with global headquarters in Shanghai, our company has subsidiaries and R&D centres across China, the United States, and other parts of the world.
Silver Sponsors
Cyclotek offers a range of radiopharmaceutical products in oncology and neurology bringing patient-centred diagnostics to life. With the unlocking of the human genome and ever more sophisticated drug development, we seek to advance therapeutic discovery, further refine diagnostic pathways and drive higher standards in personalised medicine.
Through our network of radiopharmacies in Sydney, Melbourne, Adelaide, Brisbane and Perth, GMS has Australia-wide reach to supply time-critical SPECT and PET doses to hospitals and medical imaging practices. GMS also has the Radpharm SPECT cold-kit manufacturing division in Canberra. Our collaborations with Telix, Comecer, Scintomics, IDB and IRE allow GMS to offer new and exciting tracers, technology and equipment to Australian customers.
OncoBeta® GmbH is a medical device and radiochemical company specialized on the development and commercialization of state-of-the-art therapies and products utilizing rhenium 188. Since 2014 OncoBeta has concentrated its efforts in the development and commercialization of the non-invasive, painless epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy) targeting Non-Melanoma Skin Cancers.
Future oriented, OncoBeta seeks, develops, and delivers therapies which provide painless, customized, single-session applications that achieve exceptional cosmetic results.
Bronze Sponsors
AdvanCell Isotopes is a clinical stage radiopharmaceutical company developing next-generation therapies for the treatment of cancer.
AdvanCell’s Platform technology, a world-first small footprint medical isotope generator, addresses the fundamental unmet need for cancer radionuclide therapy: the reliable supply of alpha emitting isotopes.
The platform enables the development of a pipeline of alpha radioligand therapies, linking AdvanCell’s proprietary and highly scalable isotope production to its in-house radiopharmaceutical manufacturing and clinical expertise.
Bruker offers a wide range of advanced preclinical nuclear molecular imaging solutions, such as small animal PET/CT, PET/MR and PET/SPECT/CT hybrid devices, as well as high-end PET, SPECT and CT benchtop systems to help scientists advance their research within e.g. oncology, neurology, cardiology, inflammation, infectious diseases and bone imaging.
Additionally, Bruker offers innovative software solutions for image acquisition, image viewing and data handling. As well as state of the art reconstruction algorithms, data analysis software and new AI tools that can speed up your image analysis workflow.
Come visit our booth and have a chat with to one of our NMI experts.
Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 (Cu-64) and copper-67 (Cu-67) for diagnosis and therapy.
Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as rare and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer.
Isotopia Molecular Imaging is an essential supplier for the growing field of nuclear medicine.
Driven by the need to expand healthcare providers’ power to diagnose and treat cancer, with greater precision and safety, we develop, produce, and supply cutting-edge diagnostic and therapeutic radioactive isotopes and cold kits.
Exhibitor Sponsors
Charles River Laboratories provides tailored global testing and manufacturing solutions to support clients throughout the biologic development cycle, from discovery through preclinical and clinical studies to product release. Combined with our comprehensive portfolio of products and services for microbial quality control, including Endosafe® endotoxin testing, Accugenix® microbial identification, and Celsis® microbial detection, we have the necessary tools to guide clients throughout the drug development process, leading to the release of safe and effective products, including vaccines, cell and gene therapies, and biosimilars.
Hillrom is a leading global medical technology company whose products, services and more than 10,000 employees worldwide help people get better care inside and outside the hospital. Our innovations in five core areas – Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency, and Respiratory Health – improve clinical and economic outcomes and ensure caregivers in more than 100 countries have the products they need to protect patients, speed up recoveries and manage conditions. Every day, around the world, we enhance outcomes for patients and their caregivers.
INVIA is dedicated to developing advanced non-invasive cardiac imaging software for medical professionals to optimize patient care. Physicians use our software, 4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. 4DM is available integrated with more than 40 camera, workstation, EMR and PACS manufacturers, or as a software-only solution for Windows laptops and workstations.
We developed 4DM with the patient in mind.
Trasis designs, manufactures and sells high performance radiopharmaceutical equipment: synthesizers, dose preparation equipment, shielding and accessories”.
VentMedis based in Germany is the original supplier of the large crucible used in the performance of lung ventilation studies. The VentMedis kit provides the crucible along with associated plastic administration set.
Over the past 30 years, we have forged a reputation for delivering exceptional patient care to the community. This has been achieved through our highly specialised team of Radiologists, Technologists, and Administrative staff, as well as our unwavering commitment to state-of-the-art technology and diagnostic imaging practices.
We are a part of the Sonic Healthcare group, an ASX Top 50 company, and instil their commitment to Medical Leadership in our culture and everyday practice.
We offer you quality advice, service and application support gained from over forty combined years of industry experience equipping reactors, cyclotrons, PET centres, and nuclear medicine facilities.
A growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you to find the best possible solution for your daily application.
In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production sites as well as their construction. Together with our partners we have been involved in several projects in the United States.
The team of now 10 employees worldwide is ready to support you with all your requests and is looking forward getting in contact with you.
Professional Societies
Stay Connected.
Join your fellow Nuclear Medicine peers in ANZSNM social media channels
Conference Manager
For all conference enquires, please talk to the team at: Event Studio Group Pty Ltd 60 Wellington Square, North Adelaide SA 5006 +61 8 8379 8222 ANZSNM2022@eventstudio.com.au
Privacy
To view the privacy statement, click here